Tag: Drugs and Pharmaceuticals
ECHO Connection – Cannabinoid-Based Education, Collaboration and Hope – Non-Profit Charitable Org Appoints New CEO Andrea Barnes
SAN DIEGO, Calif., Oct. 3, 2017 (SEND2PRESS NEWSWIRE) -- ECHO Connection, a non-profit charitable organization dedicated to educating the world, hosting collaborative platforms, and providing hope for those in need of cannabinoid-based therapies, announced today that it has appointed Andrea Barnes as its new CEO and President. Barnes will be speaking about the charity's work in guiding families seeking the therapeutic effects of cannabinoids by connecting them with resources that can help at the 4th Annual Cannabis World Congress & Business Exposition (CWCBE) in Boston.
Paragon BioTeck Calls Emerging Leaders to Apply for 2018 Ophthalmology Scholarship
PORTLAND, Ore., Oct. 2, 2017 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately-held pharmaceutical and medical device company, today announced the call for the next Koch Kellan Scholar. The annual Koch Kellan Scholarship honors one outstanding graduate medical student committed to elevating the standard of eye care through social responsibility and a clinical, teaching, or research career in ophthalmology. A Paragon Gives initiative, the scholarship reinforces the fundamental mission of Paragon BioTeck to drive innovations to address unmet and underserved medical needs.
Edmond Hooker, MD, Darrel Hicks, and Bruce Rippe Discuss Medical Mattress Contamination Issues on C.diff Spores and More, Aug. 1
TAMPA, Fla., July 31, 2017 (SEND2PRESS NEWSWIRE) -- C Diff Foundation's, "C. diff. Spores and More Global Broadcasting Network," is honored to announce Dr. Edmond Hooker, MD - Associate Professor of Health Services Administration at Xavier University, Darrel Hicks, a well-known hospital environment specialist and educator, and Bruce Rippe, CEO of Trinity Guardion, manufacturer of the Trinity Guardion Patient Protective Barrier, as our guest speakers on August 1, 2017.
ChemDiv Selected by Arcus Biosciences as the Sole Chemistry Provider for its Discovery Screening Collection
SAN DIEGO, Calif., June 12, 2017 (SEND2PRESS NEWSWIRE) -- ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus's growing HTS screening collection. This collaboration, which utilized Arcus's medicinal chemistry knowledge and ChemDiv's computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.
Verify Smart Corporation Signs Letter of Intent to Acquire Equity Stake and Exclusive International Reseller Rights in Med-Con Technologies, LLC
FERNLEY, Nev., June 8, 2017 (SEND2PRESS NEWSWIRE) -- Verify Smart Corporation (OTC:VSMR / OTCMKTS:VSMR) a Global innovator in financial fraud prevention and digital distribution solutions announced today that it has signed a Letter of Intent to acquire an equity stake and exclusive international reseller rights in Med-Con Technologies, LLC for cash and stock.
Medical Experts Unite Regarding Health Benefits of Testosterone Therapy in Women
IRVING, Texas, April 19, 2017 (SEND2PRESS NEWSWIRE) - BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.
Delta Care Rx Announces Patrick White, MD, as Recipient of Delta Distinguished Scholar Award
PITTSBURGH, Pa., April 18, 2017 (SEND2PRESS NEWSWIRE) -- Delta Care Rx today announced the first-ever recipient of the Delta Distinguished Scholar award. Patrick White, MD, HMDC, FACP, FAAHPM, chief medical officer of BJC Hospice, St. Louis, and assistant professor of medicine at Washington University, has received an initial $25,000 research grant, with a $500,000 lifetime potential, for study into the comparative and cost effectiveness of pharmaceuticals.
Trump’s attack on Opioid Epidemic is wrong target
CORTE MADERA, Calif., March 31, 2017 (SEND2PRESS NEWSWIRE) -- Dr. Don Harte, chiropractic activist, says Trump's new panel, headed by Chris Christie, to deal with the opioid epidemic, is "philosophically and scientifically dead wrong." Dr. Harte declares, "The reason for this epidemic is clear. Orthopedists and other doctors freely prescribe Oxycontin, Fentanyl, Soma and other opioid drugs, get their patients addicted."
U.S. Patent Ruling Affirms Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation
PORTLAND, Ore., Nov. 21, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
eAgile Inc. Announces partnership with Heinlein Plastik-Technik GmbH
GRAND RAPIDS, Mich., and ZURICH, Switzerland, Sept. 29, 2016 (SEND2PRESS NEWSWIRE) -- eAgile Inc., a global leader in radio frequency identification (RFID) technologies, announces a partnership with Heinlein Plastik-Technik GmbH to bring RFID smart packaging solutions to the European cap and closure marketplace. eSeal is the first turnkey solution engineered to integrate the benefits of RFID into the billions of caps and closures consumed by the over-the-counter pharmaceutical, nutraceutical, cosmetic and chemical manufacturers.
Pharma companies gain competitive advantage from 1 day Masterclass on Artificial Intelligence in Pharma sales and marketing
NEW YORK, N.Y., Aug. 2, 2016 (SEND2PRESS NEWSWIRE) -- Eularis announces the release of their one-day Masterclass "Using Artificial Intelligence to Transform Sales and Revenue: What Pharma Need to Know." Many Pharma sales and marketing teams do not understand the relevance, nor the critical importance, of AI to achieve stronger results in their roles, and believe it is not relevant to them or their job. This is an incorrect assumption.
Sarasota Attorney M David Shapiro Comments on Landmark $70 Million ADHD Drug Risperdal Lawsuit
SARASOTA, Fla., July 28, 2016 (SEND2PRESS NEWSWIRE) -- The Sarasota Florida attorney commented after a Philadelphia jury returned a verdict of $70 million against Johnson and Johnson for failing to warn of the risks associated for taking Risperdal. The case involved a sixteen-year-old boy who developed breast from the medication prescribed for attention deficit disorder (ADHD).
BioTE Medical Poised to Change Healthcare as it Expands into Georgia
ATLANTA, Ga., May 11, 2016 (SEND2PRESS NEWSWIRE) -- BioTE(R) Medical, a leader in bioidentical hormone replacement therapy (BHRT), is expanding its nationwide network of certified physicians into the Atlanta, Georgia market this month.
W&L Hopes Faster FDA Publication of Potential Risk Signals for SGLT2 Inhibitors: Newest – Stroke, Thromboembolic Events, Acute Kidney Injury
NEW YORK, N.Y., April 1, 2016 (SEND2PRESS NEWSWIRE) -- Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).
Paragon BioTeck Receives EN ISO 13485:2012 Certification
PORTLAND, Ore., March 29, 2016 (SEND2PRESS NEWSWIRE) -- Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, announced today that it has received EN ISO 13485:2012 certification, signifying the company's successful implementation of an effective quality management system.
eAgile Announces the Production Launch of the eSeal RFID Solution for Sealed Caps and Closures
GRAND RAPIDS, Mich. and ZURICH, Switzerland, Jan. 26, 2016 (SEND2PRESS NEWSWIRE) -- eAgile Inc., a global leader in radio frequency identification (RFID) technologies, announces the successful high-volume production launch of the eSeal heat induction solution. eSeal is the first turnkey solution engineered to integrate the benefits of RFID into the billions of caps and closures consumed by the over-the-counter pharmaceutical, nutraceutical, cosmetic and chemical manufacturers.
BioTE Medical Study Showing Promising Results for Military Veterans Diagnosed with PTSD and TBI
IRVING, Texas, Dec. 30, 2015 (SEND2PRESS NEWSWIRE) -- A current BioTE(R) Medical Combat Trauma Treatment Study (in conjunction with the Veterans Advocacy Center (VAC)) is showing promising results in helping veterans suffering from Post-Traumatic Stress Disorder (PTSD) and Traumatic Brain Injury (TBI).
Weitz and Luxenberg Adds Serious Urinary Tract Infections to SGLT2 Inhibitor Injuries Probe
NEW YORK, N.Y., Dec. 7, 2015 (SEND2PRESS NEWSWIRE) -- Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.
Harbor Compounding Pharmacy Advises About Coverage for Compounded Medications During Open Enrollment 2016
COSTA MESA, Calif., Oct. 12, 2015 (SEND2PRESS NEWSWIRE) -- Many insurance plans are dropping coverage of compounded medications, but some insurance plans still do cover for these custom formulations. Harbor Compounding Pharmacy provides resources and referrals to patients to find insurance coverage for their compounded medications during open enrollment 2016.
E-VAI – the Artificial Intelligence Platform from Eularis Changes the Rules of the Marketing in Pharma
NEW YORK, N.Y. and Tokyo, Sept. 15, 2015 (SEND2PRESS NEWSWIRE) -- Eularis announces today the release of E-VAI, the latest development in sophisticated artificial intelligence technology delivering next generation analytics and decision making to Pharma marketers globally. E-VAI changes the game for marketers struggling to understand and get value from their marketing.

























